The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.
Stephen L. Hauser, MD
Advertisement
Articles by Stephen L. Hauser, MD
The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.
The director of the UCSF Weill Institute for Neuroscience offered his perspective on data presented at MS Virtual suggesting ofatumumab’s benefit in patients with MS who were treatment naïve.
Advertisement
Latest Updated Articles
Stephen L. Hauser, MD: Fenebrutinib and BTK Inhibition in Progressive MSPublished: September 26th 2020 | Updated:
- Stephen L. Hauser, MD: Ofatumumab in Treatment-Naïve Patients With MS
Published: September 22nd 2020 | Updated:
- Stephen L. Hauser, MD: Increasing Understanding of Disease Progression in MS
Published: September 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
4
Reinforce Ocrelizumab’s Role Across the Full Spectrum of More Advanced Progressive MS: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath
5
